Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2025-10-14 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science tiendra une conférence virtuelle le jeudi 16 octobre 2025, de 14 h à 15 h CET, afin de faire le point sur l'étude de phase 1 avec AB8939
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing positive clinical trial results for their drug candidate AB8939 in combination with Venetoclax for Acute Myeloid Leukemia (AML). It details the clinical data, patient profiles, and announces an upcoming virtual conference for investors and experts. This type of announcement regarding clinical trial progress and corporate updates is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement of material information.
2025-10-14 French
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing positive initial clinical trial data for their drug candidate AB8939. It details the results of a Phase 1 study, provides expert commentary, and announces an upcoming virtual conference to discuss these findings. This type of corporate communication regarding clinical trial progress and scientific updates is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like Earnings Release or Investor Presentation.
2025-10-14 English
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2025 (ending June 30, 2025). It includes consolidated financial statements, a balance sheet, and detailed management commentary on financial performance, clinical development, and corporate events. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis for an interim period. H1 2025
2025-10-10 English
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2025 et présente un point sur ses activités
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2025 (period ending June 30, 2025) for AB Science. It includes consolidated financial statements (income statement, balance sheet data), management's discussion of financial results, and detailed updates on clinical development and corporate events. It is not a mere announcement (RPA) as it contains substantive financial data and analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report. H1 2025
2025-10-10 French
Rapport financier semestriel 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2025' (Half-Year Financial Report as of June 30, 2025) for AB Science S.A. It contains a detailed summary, management discussion on financial situation, consolidated financial statements, and an auditor's report. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-10-10 French
AB Science annonce annonce un léger décalage de la publication de son rapport financier du premier semestre 2025
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from AB Science stating that the publication of their 2025 half-year financial report is delayed and providing a new date for its release. According to the 'Menu vs Meal' rule, an announcement regarding the timing or publication of a report is classified as a Report Publication Announcement (RPA).
2025-09-30 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.